Tysabri (Natalizumab): Another Case of PML
M.S. Drug Tied to a Death
Published: March 31, 2005
By Bloomberg News
Biogen Idec and the Elan Corporation said that a third patient had developed a fatal nervous system disorder linked to the multiple sclerosis drug Tysabri, which the companies stopped selling last month.
The patient, who died in 2003, had Crohn's disease and took Tysabri in a clinical trial, said Amy Brockelman, a spokeswoman for Biogen. Tysabri won approval in November as a treatment for multiple sclerosis and the companies were studying use of the drug for other conditions.
Geoffrey C. Porges, an analyst Sanford C. Bernstein & Company, said the new information cut the chance that the companies would succeed in bringing Tysabri back to market. Biogen and Elan announced discovery of two earlier cases of the nervous system disorder.
Read the report (free registration required)
A more-detailed Bloomberg report on this case and business-world implications can be found using this link.